+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Interferons Market 2024-2028

  • PDF Icon

    Report

  • 160 Pages
  • March 2024
  • Region: Global
  • TechNavio
  • ID: 5945916
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The interferons market is forecasted to grow by USD 2.65 bn during 2023-2028, accelerating at a CAGR of 4.65% during the forecast period. The report on the interferons market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of viral infections, rising cases of autoimmune diseases, and advancements in biotechnology in developing recombinant interferons.

The interferons market is segmented as below:

By Type

  • Interferon beta
  • Interferon alfa
  • Interferon gamma

By Indication

  • Multiple sclerosis
  • Hepatitis C
  • Melanoma
  • Leukemia
  • Other indications

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the exploration of combination therapies involving interferons and other classes of drugs as one of the prime reasons driving the interferons market growth during the next few years. Also, growing emphasis on personalized medicine and increasing demand for biosimilars will lead to sizable demand in the market.

The report on the interferons market covers the following areas:

  • Interferons market sizing
  • Interferons market forecast
  • Interferons market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading interferons market vendors that include 3SBio Inc., Bayer AG, Biogen Inc., Biosidus SA, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Mega Labs SA, Merck KGaA, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Novartis AG, Pfizer Inc., PharmaEssentia Corp., Sanfer, Synairgen plc, and Zydus Lifesciences Ltd.. Also, the interferons market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global interferons market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global interferons market 2018 - 2022 ($ billion)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.3 Indication Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Indication Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Interferon beta - Market size and forecast 2023-2028
Exhibit 34: Chart on Interferon beta - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Interferon beta - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Interferon beta - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Interferon beta - Year-over-year growth 2023-2028 (%)
6.4 Interferon alfa - Market size and forecast 2023-2028
Exhibit 38: Chart on Interferon alfa - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Interferon alfa - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Interferon alfa - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Interferon alfa - Year-over-year growth 2023-2028 (%)
6.5 Interferon gamma - Market size and forecast 2023-2028
Exhibit 42: Chart on Interferon gamma - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Interferon gamma - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Interferon gamma - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Interferon gamma - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Type
Exhibit 46: Market opportunity by Type ($ billion)
Exhibit 47: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Indication
7.1 Market segments
Exhibit 48: Chart on Indication - Market share 2023-2028 (%)
Exhibit 49: Data Table on Indication - Market share 2023-2028 (%)
7.2 Comparison by Indication
Exhibit 50: Chart on Comparison by Indication
Exhibit 51: Data Table on Comparison by Indication
7.3 Multiple sclerosis - Market size and forecast 2023-2028
Exhibit 52: Chart on Multiple sclerosis - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Multiple sclerosis - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Multiple sclerosis - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Multiple sclerosis - Year-over-year growth 2023-2028 (%)
7.4 Hepatitis C - Market size and forecast 2023-2028
Exhibit 56: Chart on Hepatitis C - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Hepatitis C - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Hepatitis C - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Hepatitis C - Year-over-year growth 2023-2028 (%)
7.5 Melanoma - Market size and forecast 2023-2028
Exhibit 60: Chart on Melanoma - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Melanoma - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Melanoma - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Melanoma - Year-over-year growth 2023-2028 (%)
7.6 Leukemia - Market size and forecast 2023-2028
Exhibit 64: Chart on Leukemia - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Leukemia - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Leukemia - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Leukemia - Year-over-year growth 2023-2028 (%)
7.7 Other indications - Market size and forecast 2023-2028
Exhibit 68: Chart on Other indications - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Data Table on Other indications - Market size and forecast 2023-2028 ($ billion)
Exhibit 70: Chart on Other indications - Year-over-year growth 2023-2028 (%)
Exhibit 71: Data Table on Other indications - Year-over-year growth 2023-2028 (%)
7.8 Market opportunity by Indication
Exhibit 72: Market opportunity by Indication ($ billion)
Exhibit 73: Data Table on Market opportunity by Indication ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 111: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 112: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 113: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 114: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 3SBio Inc.
Exhibit 123: 3SBio Inc. - Overview
Exhibit 124: 3SBio Inc. - Product/Service
Exhibit 125: 3SBio Inc. - Key offerings
12.4 Bayer AG
Exhibit 126: Bayer AG - Overview
Exhibit 127: Bayer AG - Business segments
Exhibit 128: Bayer AG - Key news
Exhibit 129: Bayer AG - Key offerings
Exhibit 130: Bayer AG - Segment focus
12.5 Biogen Inc.
Exhibit 131: Biogen Inc. - Overview
Exhibit 132: Biogen Inc. - Product/Service
Exhibit 133: Biogen Inc. - Key news
Exhibit 134: Biogen Inc. - Key offerings
12.6 Biosidus SA
Exhibit 135: Biosidus SA - Overview
Exhibit 136: Biosidus SA - Product/Service
Exhibit 137: Biosidus SA - Key offerings
12.7 Bristol Myers Squibb Co.
Exhibit 138: Bristol Myers Squibb Co. - Overview
Exhibit 139: Bristol Myers Squibb Co. - Product/Service
Exhibit 140: Bristol Myers Squibb Co. - Key news
Exhibit 141: Bristol Myers Squibb Co. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 142: F. Hoffmann La Roche Ltd. - Overview
Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 144: F. Hoffmann La Roche Ltd. - Key news
Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus
12.9 Mega Labs SA
Exhibit 147: Mega Labs SA - Overview
Exhibit 148: Mega Labs SA - Product/Service
Exhibit 149: Mega Labs SA - Key offerings
12.10 Merck KGaA
Exhibit 150: Merck KGaA - Overview
Exhibit 151: Merck KGaA - Business segments
Exhibit 152: Merck KGaA - Key news
Exhibit 153: Merck KGaA - Key offerings
Exhibit 154: Merck KGaA - Segment focus
12.11 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
Exhibit 155: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Overview
Exhibit 156: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Product/Service
Exhibit 157: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Key offerings
12.12 Novartis AG
Exhibit 158: Novartis AG - Overview
Exhibit 159: Novartis AG - Business segments
Exhibit 160: Novartis AG - Key news
Exhibit 161: Novartis AG - Key offerings
Exhibit 162: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 163: Pfizer Inc. - Overview
Exhibit 164: Pfizer Inc. - Product/Service
Exhibit 165: Pfizer Inc. - Key news
Exhibit 166: Pfizer Inc. - Key offerings
12.14 PharmaEssentia Corp.
Exhibit 167: PharmaEssentia Corp. - Overview
Exhibit 168: PharmaEssentia Corp. - Product/Service
Exhibit 169: PharmaEssentia Corp. - Key offerings
12.15 Sanfer
Exhibit 170: Sanfer - Overview
Exhibit 171: Sanfer - Product/Service
Exhibit 172: Sanfer - Key offerings
12.16 Synairgen plc
Exhibit 173: Synairgen plc - Overview
Exhibit 174: Synairgen plc - Product/Service
Exhibit 175: Synairgen plc - Key offerings
12.17 Zydus Lifesciences Ltd.
Exhibit 176: Zydus Lifesciences Ltd. - Overview
Exhibit 177: Zydus Lifesciences Ltd. - Business segments
Exhibit 178: Zydus Lifesciences Ltd. - Key offerings
Exhibit 179: Zydus Lifesciences Ltd. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 180: Inclusions checklist
Exhibit 181: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 182: Currency conversion rates for US$
13.4 Research methodology
Exhibit 183: Research methodology
Exhibit 184: Validation techniques employed for market sizing
Exhibit 185: Information sources
13.5 List of abbreviations
Exhibit 186: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global interferons market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Indication Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Type - Market share 2023-2028 (%)
Exhibits 31: Data Table on Type - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on Interferon beta - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Interferon beta - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Interferon beta - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Interferon beta - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Interferon alfa - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Interferon alfa - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Interferon alfa - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Interferon alfa - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Interferon gamma - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Interferon gamma - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Interferon gamma - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Interferon gamma - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Type ($ billion)
Exhibits 47: Data Table on Market opportunity by Type ($ billion)
Exhibits 48: Chart on Indication - Market share 2023-2028 (%)
Exhibits 49: Data Table on Indication - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Indication
Exhibits 51: Data Table on Comparison by Indication
Exhibits 52: Chart on Multiple sclerosis - Market size and forecast 2023-2028 ($ billion)
Exhibits 53: Data Table on Multiple sclerosis - Market size and forecast 2023-2028 ($ billion)
Exhibits 54: Chart on Multiple sclerosis - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Multiple sclerosis - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Hepatitis C - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on Hepatitis C - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on Hepatitis C - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Hepatitis C - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Melanoma - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on Melanoma - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on Melanoma - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Melanoma - Year-over-year growth 2023-2028 (%)
Exhibits 64: Chart on Leukemia - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Data Table on Leukemia - Market size and forecast 2023-2028 ($ billion)
Exhibits 66: Chart on Leukemia - Year-over-year growth 2023-2028 (%)
Exhibits 67: Data Table on Leukemia - Year-over-year growth 2023-2028 (%)
Exhibits 68: Chart on Other indications - Market size and forecast 2023-2028 ($ billion)
Exhibits 69: Data Table on Other indications - Market size and forecast 2023-2028 ($ billion)
Exhibits 70: Chart on Other indications - Year-over-year growth 2023-2028 (%)
Exhibits 71: Data Table on Other indications - Year-over-year growth 2023-2028 (%)
Exhibits 72: Market opportunity by Indication ($ billion)
Exhibits 73: Data Table on Market opportunity by Indication ($ billion)
Exhibits 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 77: Chart on Geographic comparison
Exhibits 78: Data Table on Geographic comparison
Exhibits 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 111: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 112: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits 113: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 114: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 115: Market opportunity By Geographical Landscape ($ billion)
Exhibits 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 117: Impact of drivers and challenges in 2023 and 2028
Exhibits 118: Overview on Criticality of inputs and Factors of differentiation
Exhibits 119: Overview on factors of disruption
Exhibits 120: Impact of key risks on business
Exhibits 121: Vendors covered
Exhibits 122: Matrix on vendor position and classification
Exhibits 123: 3SBio Inc. - Overview
Exhibits 124: 3SBio Inc. - Product/Service
Exhibits 125: 3SBio Inc. - Key offerings
Exhibits 126: Bayer AG - Overview
Exhibits 127: Bayer AG - Business segments
Exhibits 128: Bayer AG - Key news
Exhibits 129: Bayer AG - Key offerings
Exhibits 130: Bayer AG - Segment focus
Exhibits 131: Biogen Inc. - Overview
Exhibits 132: Biogen Inc. - Product/Service
Exhibits 133: Biogen Inc. - Key news
Exhibits 134: Biogen Inc. - Key offerings
Exhibits 135: Biosidus SA - Overview
Exhibits 136: Biosidus SA - Product/Service
Exhibits 137: Biosidus SA - Key offerings
Exhibits 138: Bristol Myers Squibb Co. - Overview
Exhibits 139: Bristol Myers Squibb Co. - Product/Service
Exhibits 140: Bristol Myers Squibb Co. - Key news
Exhibits 141: Bristol Myers Squibb Co. - Key offerings
Exhibits 142: F. Hoffmann La Roche Ltd. - Overview
Exhibits 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 144: F. Hoffmann La Roche Ltd. - Key news
Exhibits 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 146: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 147: Mega Labs SA - Overview
Exhibits 148: Mega Labs SA - Product/Service
Exhibits 149: Mega Labs SA - Key offerings
Exhibits 150: Merck KGaA - Overview
Exhibits 151: Merck KGaA - Business segments
Exhibits 152: Merck KGaA - Key news
Exhibits 153: Merck KGaA - Key offerings
Exhibits 154: Merck KGaA - Segment focus
Exhibits 155: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Overview
Exhibits 156: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Product/Service
Exhibits 157: NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC - Key offerings
Exhibits 158: Novartis AG - Overview
Exhibits 159: Novartis AG - Business segments
Exhibits 160: Novartis AG - Key news
Exhibits 161: Novartis AG - Key offerings
Exhibits 162: Novartis AG - Segment focus
Exhibits 163: Pfizer Inc. - Overview
Exhibits 164: Pfizer Inc. - Product/Service
Exhibits 165: Pfizer Inc. - Key news
Exhibits 166: Pfizer Inc. - Key offerings
Exhibits 167: PharmaEssentia Corp. - Overview
Exhibits 168: PharmaEssentia Corp. - Product/Service
Exhibits 169: PharmaEssentia Corp. - Key offerings
Exhibits 170: Sanfer - Overview
Exhibits 171: Sanfer - Product/Service
Exhibits 172: Sanfer - Key offerings
Exhibits 173: Synairgen plc - Overview
Exhibits 174: Synairgen plc - Product/Service
Exhibits 175: Synairgen plc - Key offerings
Exhibits 176: Zydus Lifesciences Ltd. - Overview
Exhibits 177: Zydus Lifesciences Ltd. - Business segments
Exhibits 178: Zydus Lifesciences Ltd. - Key offerings
Exhibits 179: Zydus Lifesciences Ltd. - Segment focus
Exhibits 180: Inclusions checklist
Exhibits 181: Exclusions checklist
Exhibits 182: Currency conversion rates for US$
Exhibits 183: Research methodology
Exhibits 184: Validation techniques employed for market sizing
Exhibits 185: Information sources
Exhibits 186: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global interferons market: 3SBio Inc., Bayer AG, Biogen Inc., Biosidus SA, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Mega Labs SA, Merck KGaA, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Novartis AG, Pfizer Inc., PharmaEssentia Corp., Sanfer, Synairgen plc, and Zydus Lifesciences Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is exploration of combination therapies involving interferons and other classes of drugs.'

According to the report, one of the major drivers for this market is the increasing prevalence of viral infections.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3SBio Inc.
  • Bayer AG
  • Biogen Inc.
  • Biosidus SA
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Mega Labs SA
  • Merck KGaA
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Novartis AG
  • Pfizer Inc.
  • PharmaEssentia Corp.
  • Sanfer
  • Synairgen plc
  • Zydus Lifesciences Ltd.